You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

LARIN 1.5 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Larin 1.5 patents expire, and what generic alternatives are available?

Larin 1.5 is a drug marketed by Novast Labs and is included in one NDA.

The generic ingredient in LARIN 1.5 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LARIN 1.5?
  • What are the global sales for LARIN 1.5?
  • What is Average Wholesale Price for LARIN 1.5?
Summary for LARIN 1.5
US Patents:0
Applicants:1
NDAs:1
DailyMed Link:LARIN 1.5 at DailyMed
Drug patent expirations by year for LARIN 1.5

US Patents and Regulatory Information for LARIN 1.5

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novast Labs LARIN 1.5/30 ethinyl estradiol; norethindrone acetate TABLET;ORAL-21 202996-001 Mar 20, 2014 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.